Michael Craig Cox, PharmD, MHSc, BCOP joined Circle Pharma in July 2023 as our Senior Vice President, Head of Early Development. During a nearly 20-year career in the pharmaceutical industry, he has led the clinical development, product launches, and life cycle management of numerous oncology products including tovorafenib, selpercatinib (Retevmo®), larotrectinib (VITRAKVI®), radium-223 (Xofigo®), regorafenib (Stivarga®), sorafenib (Nexavar®), cetuximab (ERBITUX®), denosumab (XGEVA®), and darbepoetin alfa (Aranesp®). Dr. Cox has co-authored papers published in The New England Journal of Medicine, Lancet Oncology, the Journal of Clinical Oncology, and other prestigious medical journals. Prior to joining Circle Pharma, he was Vice President, Clinical Development at Day One Biopharmaceuticals, where he was responsible for the clinical strategy and execution of the FIREFLY-1 and LOGGIC/FIREFLY-2 pediatric low-grade glioma registrational programs as well as building the clinical science, clinical development and medical affairs groups. Prior to joining Day One, Dr. Cox held global and regional clinical development and medical affairs positions of increasing responsibility at Loxo Oncology, Inc (acquired by Eli Lilly and Company), South San Francisco, California; Bayer Pharmaceuticals, Basel, Switzerland; Merck KGaA, Darmstadt, Germany; and Amgen Inc., Thousand Oaks, California.

Michael holds a PharmD from Ohio Northern University’s Raabe College of Pharmacy and an MHSc in Clinical Research from Duke University’s School of Medicine, and is a board-certified oncology pharmacist. Dr. Cox completed post-graduate training at Mission Hospitals, the University of Pittsburgh Medical Center, and the National Cancer Institute.